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Summary
INTRODUCTION: The wearable cardioverter-defibrillator
(WCD) has established itself in treatment of potentially life-
threatening ventricular arrhythmias, when implantation of
an implantable cardioverter-defibrillator (ICD) is not war-
ranted. Careful patient selection for this therapy is crucial,
but unfortunately very little information from randomised
controlled trials is available to guide clinical decision-mak-
ing. Consequently, data from real-world patient registries
play a more important role in this context.
MATERIALS AND METHODS: A retrospective observa-
tional study was conducted at the University Hospital of
Zurich and the GZO Regional Healthcare Centre in Wet-
zikon. Clinical databases were screened for patients with
a history of WCD use from the time of its approval in
Switzerland in July 2014 until February 2018. Baseline
characteristics, WCD data and outcome data, with an em-
phasis on ICD implantation and ICD therapies, were col-
lected and analysed.
RESULTS: Two-hundred and seven patients were includ-
ed in the primary analysis. Eighty-six percent were male
and the mean age was 58 ± 13 years. The underlying
heart disease was ischaemic cardiomyopathy (ICM), non-
ischaemic cardiomyopathy (NICM) and congenital/inher-
ited heart diseases in 60, 35 and 5%, respectively. The
most common indication for WCD use was heart failure
with an ejection fraction (EF) <35% due to ICM or NICM
(43 and 27%, respectively). Three of the 207 patients re-
ceived an appropriate shock over a median WCD wear-
time of 62 days (interquartile range [IQR] 35–95). No in-
appropriate shocks were registered. Median average daily
wear-time was 22.6 hours (IQR 19.9–23.2) and was sig-
nificantly shorter for patients for whom WCD discontinua-
tion was due to comfort issues (17 patients, p = 0.003). Af-
ter the end of WCD therapy, 48% were implanted with an
ICD. In those receiving an ICD, the rate of appropriate ICD
therapies (either shock or antitachycardia pacing) was 8%
during a median follow-up of 110 days (IQR 23–421).
CONCLUSION: The WCD is safe and effective in ter-
minating malignant ventricular arrhythmias. A substantial
subgroup of patients, however, discontinued WCD use
prematurely because of comfort issues. This subset of pa-
tients deserves further attention in clinical practice to en-
sure therapy adherence.
Keywords: wearable cardioverter defibrillator, sudden
cardiac death, implantable cardioverter defibrillator, sub-
cutaneous implantable cardioverter defibrillator, implanta-
tion rate, outcome
Introduction
Sudden cardiac death (SCD) is a catastrophic event caused
by malignant ventricular tachyarrhythmias. Implantable
cardioverter-defibrillator (ICD) therapy is indicated in se-
lected patients for the prevention of SCD. Selection is
mainly based on left ventricular function, namely systolic
left ventricular ejection fraction (EF). Landmark trials
showed that patients with severely reduced EF (<35%) and
symptomatic heart failure have a survival benefit after im-
plantation of an ICD [1, 2]. Too early implantation, on the
other hand, has shown no benefit and is contraindicated
[3, 4]. Therefore, 40- to 90-day waiting periods are recom-
mended in patients after myocardial infarction (MI), revas-
cularisation and newly diagnosed cardiomyopathy. Uncer-
tainty remains as to which of these patients with reduced
EF are nevertheless at elevated risk for SCD within this 40
to 90 days period.
In certain cases the risk of SCD is estimated to be high and
temporary protection is deemed necessary. The wearable
cardioverter-defibrillator (WCD, LifeVest, ZOLL Pitts-
burgh, PA) can provide temporary protection in such cases.
Another possible indication for its use is the necessity for
ICD explantation due to lead infection or malfunction, un-
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til re-implantation can ensue. The 2016 European guide-
lines outline the recommended use of the WCD in such se-
lected cases [5]. Nonetheless, randomised controlled data
are scarce in this area. The recently published VEST trial
is to date the only randomised controlled trial investigat-
ing WCD use, although only patients with ischaemic heart
disease (ischaemic cardiomyopathy; ICM) were investigat-
ed [6]. Therefore, contemporary real-world data including
also non-ischaemic cardiomyopathy (NICM) patients may
provide helpful information to close an apparent knowl-
edge gap.
The WCD was approved in Switzerland in July 2014. The
aim of this study was to provide first insights into the use
of the WCD in Switzerland, with an emphasis on patient
outcome.
Material and methods
Study design and population
This was a retrospective observational study reporting on
initial experience with the use of the WCD in Switzerland.
We report data collected at a tertiary medical care centre,
the University Hospital Zurich, and its affiliated teaching
hospital, the GZO Regional Health Centre in Wetzikon,
Switzerland. All patients who received a WCD between its
approval in June 2014 and February 2018 were screened
for inclusion. Patients with incomplete data on WCD use
or refusal to participate were excluded. The study was ap-
proved by the local ethics committee and conforms to the
Declaration of Helsinki as revised in 2013. This study was
conducted according to the STROBE statement.
Wearable cardioverter-defibrillator
The technical and practical aspects of the WCD have pre-
viously been reported [7]. In brief, arrhythmia recognition
is based on an algorithm analysing heart rate and QRS
morphology. If ventricular tachycardia or ventricular fibril-
lation detected, sequential acoustic and vibrational alarms
are activated and an automatic event is registered and sent
to the LifeVest Network via wireless connection. In the
event of a haemodynamically stable tachyarrhythmia or a
false alarm (absence of tachycardia), patients are instructed
to activate the device’s response button to withhold shock
administration. If the patient fails to push the response but-
ton (i.e., loss of consciousness), up to five biphasic shocks
(75 to 150 Joules) may be delivered after detection of a
30-second arrhythmia and confirmation period. The de-
fault settings for the detection of ventricular tachycardia or
fibrillation are 150 and 200 beats per minute, respectively.
The device also has a bradycardia/asystole detection func-
tion, but provides no pacing capabilities.
Data collection
Data were entered using the REDCap software (Vanderbilt,
Nashville, TN, USA); access was provided by the Clinical
Trials Centre Zurich. The time period for data collection
was between May and November 2018. The electronic
clinical records of all included patients were reviewed.
Baseline characteristics included age, body mass index
(BMI), sex, underlying heart disease, indication for WCD
use, EF (measured with either echocardiography or mag-
netic resonance imaging), medical therapy and history of
supraventricular tachycardia before first wearing the
WCD. Underlying heart disease was categorised as is-
chaemic cardiomyopathy (ICM), non-ischaemic cardiomy-
opathy (NICM) and congenital/inherited heart disease ac-
cording to the diagnosis made by the treating physicians.
The indication for WCD use was categorised as follows:
– Existing ICD indication and bridging needed because of
ICD infection or infection at the time of planned ICD
implantation, bridging to planned heart transplantation
or bridging for other reasons
– New-onset heart failure due to ICM with an EF ≤35%
after myocardial infarction (MI), and/or percutaneous
coronary intervention and/or coronary artery bypass
graft operation
– New-onset heart failure due to NICM with an EF ≤35%
– New-onset heart failure due to congenital/inherited
heart disease with an EF ≤35%
– Risk stratification indicating patient to be at high risk
for SCD
The manufacturer provided data on WCD use from the
WCD database. This included average wear-time calculat-
ed as the cumulative wear hours divided by the wear dura-
tion, total wear-days, number of events (automatic, manu-
al), number of registered asystoles, number of (appropriate
or inappropriate) therapies and the rhythm tracing of every
event.
Patient outcome data were collected from electronic med-
ical records. EF measurements with either echocardiog-
raphy or magnetic resonance imaging after cessation of
WCD use, reason for WCD discontinuation, incidence and
type of device implantation after WCD use including de-
vices without a defibrillator function (categorised as sin-
gle-chamber ICD [SC-ICD]; dual-chamber ICD [DC-
ICD]; subcutaneous ICD [S-ICD]; cardiac
resynchronisation therapy [CRT] pacemaker [CRT-P] and
CRT defibrillator [CRT-D]), time to device implantation
after WCD discontinuation, number of appropriate and in-
appropriate therapies by the ICD, incidence of heart trans-
plantation and number of patients deceased at the time
of data collection of any cause. Clinical records were re-
viewed to determine the reason if no ICD was implanted.
Assessment of EF after WCD use was not routinely per-
formed in patients with a normal EF before WCD use in
the two institutions. The reason for WCD discontinuation
was categorised as: (1) implantation of an ICD, (2) im-
provement of EF obviating ICD implantation, (3) termina-
tion of risk stratification without an indication for ICD im-
plantation, (4) comfort issues and patient choice and (5)
other reasons.
Statistical analysis
This was primarily a descriptive statistical analysis. Cat-
egorical variables were reported as frequencies (percent-
age), continuous variables as means ± standard deviation
or as medians (interquartile range [IQR], range). Ex-
ploratory statistical analysis was performed by comparing
continuous data using Student’s t test or the Mann-Whitney
U test, as appropriate, and categorical data using Fishers
exact test or the chi-square test depending on the number
of groups. Correlation was calculated using Pearson’s co-
efficient. Cases with missing data were excluded from sta-
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tistical analysis. A two sided p value <0.05 was considered
statistically significant. All statistical analyses were con-
ducted using SPSS version 21 (IBM Corp., Armonk, NY,
USA).
Results
Baseline data – before WCD use
A total of 227 patients wore a WCD between July 2014
and February 2018 and were screened for inclusion and ex-
clusion criteria. A total of 207 patients were finally select-
ed for our primary analysis. Five patients refused partici-
pation and 15 patients had incomplete WCD data because
they were still wearing the device at the time of data collec-
tion, leading to their exclusion. The mean age of the study
population was 58 ± 13 years, and 86% were male. Further
baseline characteristics are shown in table 1.
The most frequent indications for WCD use were either
newly diagnosed ICM with EF ≤35% or NICM with EF
≤35%, followed by bridging either due to infection,
planned heart transplantation or other reasons, and risk
stratification in patients at presumed increased risk for
SCD (fig. 1).
WCD data
Patients wore the WCD for a median of 62 days (IQR
35–95, range 1–355) with a median daily wear-time of
22.6 hours (IQR 19.9–23.2, range 2.3–23.8). There was a
weak positive correlation between the number of days that
the WCD was worn and the daily wear-time (r = 0.179,
p = 0.01). The mean number of automatic events (thus an
alarm) per patient was 23 ± 56. Patients with ICM had sig-
nificantly more automatic alarms than the rest of the study
population (31 vs 12, p = 0.017). There was no associa-
tion between the mean number of automatic events and the
prevalence of supraventricular tachycardia (18 vs 30, p =
0.197). The device registered a total of 86 asystole events
in 5 patients. Of all asystole alarms registered in the cohort,
85 (99%) were due to undersensing of QRS complexes.
The remaining one alarm was triggered by severe brady-
cardia. Eighty-one of these (94%) were registered in a sin-
gle patient.
None of the patients had a fatal outcome during WCD use.
Three patients (1.4%) received an appropriate shock by the
WCD. The underlying arrhythmia was ventricular tachy-
cardia in two patients (patients 59 and 205) and ventricu-
lar fibrillation in the third patient (patient 207), with suc-
cessful termination by the first shock after 215, 89 and 63
seconds, respectively. The clinical characteristics and out-
comes of these patients are shown in table 2. No inappro-
priate shocks were administered in our study population.
Fifty-nine patients (28%) wore the device longer than the
standard 90 days, with a median duration of 119 days (IQR
100–137, range 91–355). The most common underlying
heart disease in these patients was ICM (34 patients, 57%).
No shocks were given in any of these patients with pro-
longed WCD use.
Figure 1: Indication for WCD use (n = 207). Data are expressed
as percentage of total population (n = 207). EF = ejection fraction;
PCI = percutaneous coronary intervention; CABG = coronary
artery bypass graft; HTX = heart transplantation
Table 1: Baseline patient characteristics (n = 207).
Variable
Age (years) 58 ± 13
Women 29 (14)
Body mass index (kg/m2) 27 ± 6
Baseline ejection fraction (%) 32 ± 13
Primary underlying heart disease Ischaemic 124 (60)
Non-ischaemic 74 (35)
Congenital/inherited 9 (5)
Cardiovascular medication Beta-blocker 185 (89)
ACE inhibitor or ARB 176 (85)
Aldosterone antagonist 114 (55)
Sacubitril/Valsartan 9 (4)
Diuretic 152 (73)
Antiplatelet therapy 128 (62)
Vitamin K antagonist 64 (31)
Non-vitamin K antagonist oral anticoagulant 32 (16)
Statin 135 (65)
Amiodarone 45 (22)
Calcium channel blocker 16 (8)
Supraventricular tachycardia Atrial fibrillation 59 (29)
Atrial flutter 21 (10)
Other* 6 (3)
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker
Data are expressed as mean ± standard deviation or n (percentage).
* Other supraventricular tachycardia: ectopic atrial tachycardia: atrioventricular (nodal) re-entry tachycardia.
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Outcome data – after WCD use
WCD discontinuation
Reasons for WCD discontinuation were implantation of
an ICD (87 patients, 42%), improvement in EF obviating
the indication for ICD implantation (64 patients, 31%), pa-
tient discomfort (17 patients, 8%) and other reasons (39 pa-
tients, 19%, including four patients for whom no follow-up
was available). Patients stopping WCD use because of dis-
comfort (n = 17, 8%) wore the device for a significantly
shorter period (42 vs 72 days, p = 0.013), had a lower aver-
age daily wear-time (18 vs 21 hours per day, p = 0.003; fig.
2) and less often underwent ICD implantation (3/99 vs 13/
104, p = 0.017), although there was no significant differ-
ence between the groups in baseline characteristics, in EF
at follow-up (35 vs 38%, p = 0.34), or the number of auto-
matic events (alarms) (19 vs 23, p = 0.781).
At the time of WCD discontinuation, EF had improved by
a mean of 7 ± 10% in patients for whom follow-up mea-
surements were available (184 patients, 89% of total study
population). Patients with ICM had significantly less im-
provement in EF than the rest of the study population (5 vs
9%, p = 0.012).
Device implantation
One hundred patients (48%) of the total population were
implanted with a device (in one case without defibrillator
function) after a median of 0 days (IQR 0–0, range 0–585)
following WCD discontinuation. Thirteen patients (6%)
stopped WCD use for reasons other than ICD implantation,
but were still implanted with a device after a median of 71
Figure 2: Distribution of mean wear hours by WCD discontinuation
because of wear discomfort or other reasons.
days (IQR 21–144, range 0–585). The implanted devices
were: 29 (14%) SC-ICD, 29 (14%) DC-ICD, 21 (10%) S-
ICD, 20 (10%) CRT-D and 1 (0.5%) CRT-P. Median fol-
low-up was 431 days (IQR 204–707, range 8–1237) for
patients with device implantation. During this period, five
patients (2.4%) had appropriate shocks, three patients ap-
propriate antitachycardia pacing (ATP) intervention (1.4%)
and two patients had inappropriate shocks (1%), Median
time to ICD therapy was 110 days (IQR 23–421, range
6–1035).
Of the 103 patients who were not implanted with any de-
vice, 82 (79%) had no indication for device implantation
due to EF recovery above 35% or completed risk stratifi-
cation with no elevated arrhythmogenic risk, refused ICD
implantation (n = 11, 10%) or had various reasons for not
receiving an ICD such as technical reasons, or low life-ex-
pectancy (n = 10, 10%). Patients implanted with an ICD
were older (60 vs 56 years, p = 0.024), had a lower EF at
the time of WCD discontinuation (34 vs 42%, p <0.001)
and significantly less improvement in EF from baseline (3
vs 11%, p <0.001). The remaining four patients of the total
cohort (n = 207) had an unknown outcome after discontin-
uing WCD use and device implantation status was there-
fore missing.
Heart transplantation and mortality
During the observational period, three patients (5.3%) re-
ceived a heart transplant for ICM, cardiac sarcoidosis and
ICM/valvular heart disease. Of these patients, one received
the WCD as bridge to heart transplantation, one as bridge
after explantation of an infected ICD and one because of
newly diagnosed ICM with EF <35%. Of these patients,
one received an appropriate shock by the WCD and after-
wards by the implanted S-ICD (patient 205 in table 2).
Fifteen patients of the total cohort (7.2%) died during the
study period. The underlying heart disease was ICM in
nine patients (60%), NICM in five patients (33%) and con-
genital heart disease in one patient (6.6%). Only one of
these patients had appropriate WCD therapy (patient 205
in table 2). Ten out of these 15 patients (66%) had an ICD
implanted as compared with the remaining patients (89/
188, 47%), which did not significantly differ (p = 0.184).
Eight of these ten had no treatment by the implanted de-
vice, one patient had an appropriate shock (patient 205 in
table 2), and one patient had an appropriate ATP therapy.
Exploratory statistical analysis revealed that deceased pa-
tients were less likely to take beta-blockers (10/15 vs 171/
188, p = 0.004), wore the WCD for a shorter duration (46
vs 72 days, p = 0.046), and had a lower improvement in EF
Table 2: Characteristics of patients with appropriate therapy by the WCD.
Patient Age
(years)
Sex Heart dis-
ease
Indication for
WCD
EF (%) Time to therapy
(days)
Antiarrhythmic
medication
Device im-
planted
Duration of
follow-up
(days)
Outcome
59 64 Male HNOCM Device-explanta-
tion due to infec-
tion
25 30 Amiodarone S-ICD 713 Deceased, no
further thera-
pies
205 72 Male ICM, VHD Device-explanta-
tion due to infec-
tion
27 4 Amiodarone, beta
blocker
S-ICD 45 Appropriate
shock by S-
ICD
207 60 Male DCM EF <35% 13 66 Amiodarone, beta
blocker
CRT-D 546 No further ther-
apies
DCM = dilated cardiomyopathy; HNOCM = hypertrophic non-obstructive cardiomyopathy; ICM = ischaemic cardiomyopathy; VHD = valvular heart disease; S-ICD = subcutaneous
implantable cardioverter-defibrillator; CRT-D = cardiac resynchronisation therapy with defibrillator
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at follow-up (0.3. vs 7.8%, p = 0.011), but were otherwise
similar in clinical characteristics to the patients still alive
at the time of data collection.
Discussion
This study has following main characteristics: it is the first
report on the use of the WCD in Switzerland with a study
population comparable to other larger studies in this topic;
the data suggest that the WCD is safe and effective in the
treatment of life-threatening ventricular arrhythmias; com-
fort issues with the use of the WCD affect a relevant sub-
group of patients who possibly are at a higher risk for ther-
apy non-adherence.
The most common indication for WCD use was low EF
due to either newly diagnosed ICM (60%) or NICM (35%)
in our study population. At the time of starting WCD use,
guideline recommended medical therapy of heart failure
had begun in the majority of patients (table 1) and EF had
improved, obviating the need to implant an ICD in 39%
of all patients at follow-up. No patients had a fatal out-
come while using the WCD and no inappropriate shocks
were administered. Furthermore, an appropriate shock rate
of only 1.4% with effective termination of tachycardia sug-
gests that the WCD is efficacious. This low rate of ther-
apy, on the other hand, suggests that patient selection is
key. Randomised controlled data are necessary to deter-
mine which patients truly benefit from the use of a WCD,
and which patients’ risk of SCD is effectively elevated.
The only randomised controlled trial investigating its use
to date is the VEST trial [6]. It failed to show a signifi-
cant reduction in arrhythmic death in patients with severe-
ly reduced EF during the early post-myocardial infarction
phase with use of the WCD. Of note, the VEST study re-
ported a similar appropriate shock rate to our study (1.9%).
Appropriate shock rates reported in real-world registries
are also similar, ranging from 1.5 to 4.7% [8–11]. These
findings suggest that our Swiss study population is repre-
sentative of an “average” WCD-wearing population.
In our cohort a high adherence (>22 hours per day) to
WCD use was detected over a median wear-time of 2
months. The VEST trial reported a lower compliance rate
at a median of 18 hours (IQR 3.8–22.7). Wässnig et al. re-
ported on the largest European population with a history
of WCD use to date [8]. They included 6043 patients with
a history of WCD use for any indication. The proportion
of patients with ICM was 26.9%. Adherence to the pre-
scribed WCD was excellent at 23.1 hours (IQR 21–23.7).
The discrepancy in adherence rates reported by Olgin et
al. and Wässnig at al. and our findings is most likely due
to the study design of the VEST trial. Compliance with
WCD therapy is understandably higher in patients active-
ly choosing this therapy option than in patients randomised
to its use. In the real world, WCD use is often terminated
in patients who do not wear the device owing to futility.
Another finding of our study was that patients with longer
WCD wear-times had a significantly higher therapy com-
pliance, including permanent ICD implantation. This is in
line with previous findings [8, 9, 12, 13] and may indicate
a subgroup of patients who have a higher adherence to pre-
scribed therapy. These patients may actually benefit from
prolonged bridging with the goal of up-titration of optimal
medical therapy to obviate the need for ICD implantation
[14–17].
A clinically relevant issue with the use of the WCD is the
discomfort reported by patients. In the literature, comfort
issues commonly referred to skin rash caused by the vest
or false alarms due to automatic event detection [18]. This
can lead to reduced compliance and premature interruption
of therapy. Published data on the comfort issue are scarce
and reported rates of WCD discontinuation due to discom-
fort ranged from 7 to 22% [13, 18–21]. This is the first
study to report on ICD implantation after discontinuation
of WCD due to patient discomfort. Comfort issues were
the primary cause of stopping WCD use in 8% of our total
study population. These patients also wore the device for
a shorter period and had significantly lower wear compli-
ance (fig. 2). Furthermore, we found that significantly few-
er of these patients were implanted with an ICD in spite
of similar underlying heart disease. Although none of these
patients died during follow-up, the lower rate of ICD im-
plantation is noteworthy. A third of them were not implant-
ed as a result of patient choice, despite an existing indica-
tion according to current guidelines. Effort should be made
to identify such patients early as they may be at increased
risk for adverse outcome. This subset may especially bene-
fit from proper patient education and support. In our opin-
ion, beside the underlying cardiac condition, assessment of
patients’ adherence prior to WCD use is key for selection.
A benefit from its use is only present when patients tru-
ly wear it and, according to these findings, this wear rate
could have an influence on further management.
To our knowledge, our study is the largest to date reporting
on both ICD implantation rate and the type of device im-
planted. Reported implantation rates after WCD use
ranged from 32 to 55% [9, 10, 16, 17, 22]. In our study,
48% of all patients were eventually implanted with an ICD.
Over half of these patients were implanted with a transve-
nous ICD, a quarter received an S-ICD and another quar-
ter a CRT-D. In comparison, Duncker et al. reported a low-
er (37%) implantation rate, 29% of which were CRT-D
(the remaining were ICDs of any type) [16]. Interesting-
ly, Röger at al. reported a similar 51% implantation rate,
of which 22% were CRT-D. They however also chose an
S-ICD in 55% of implanted cases [10]. They justified the
high rate of S-ICD implantation by analysing the rate of
bradyarrhythmias with the WCD. Even though the base-
line characteristics in both studies were similar, it is un-
clear how many patients in the study of Röger et al. were
implanted owing to an elevated risk of bloodstream infec-
tions, which is a common reason for subcutaneous device
implantation. Ultimately, the most probable reason for the
different ICD implantation rates is institutional and reim-
bursement differences. Although the S-ICD is a valuable
alternative with probably fewer lead-associated complica-
tions such as blood stream infections, the lack of brady-
or tachypacing can be a disadvantage of this device [23].
In our study population, 19% of S-ICDs were implanted
specifically after a lead-associated infection.
Patients with a fatal outcome during follow-up wore the
WCD for a significantly shorter time. They had a rate of
administered WCD and ICD therapies comparable to those
of patients without a fatal outcome. These findings sug-
gest a high portion of non-arrhythmic deaths, similar to re-
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ports in the VEST trial. The significance of non-arrhyth-
mic death in these severely ill patients has previously been
examined in the DINAMIT and IRIS studies for ICM, and
in the DEFINITE trial in NICM [3, 4, 24]. This again high-
lights the necessity of more randomised controlled trials to
facilitate patient selection for the use of the WCD. Predic-
tors of mortality have recently been identified by Kutyifa
et al. [25]. They found that a history of syncope, lack of
beta-blocker use and congenital/inherited heart disease vs
other indications were associated with an increased mor-
tality. Our findings were similar only with regard to beta-
blocker use, since fewer patients with fatal outcomes took
beta-blockers at baseline. The reason for the shorter WCD
wear-time in these patients in our cohort, however, is un-
clear.
The major limitation of this study was that cause of death
was often not available and hence not systematically as-
sessed. This is largely attributed to the retrospective study
design. Furthermore, for the same reason, loss of data is a
possibility although patients prescribed a WCD are usual-
ly subject to close and regular follow-up. For the uncon-
founded assessment of mortality in patients using a WCD,
more randomised controlled data are needed.
In conclusion, although the WCD is safe and effective in
terminating malignant ventricular arrhythmias, a substan-
tial subgroup of patients discontinued WCD use prema-
turely owing to comfort issues. This subset of patients may
have an increased risk for adverse outcome. Efforts should
be made to identify these patients so that early interven-
tions through patient education and close follow-up can
prevent a deleterious outcome.
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